This meeting took place in 2018


Here are the related meetings in 2019:
Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity (B3)
Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2)
Innate and Non-Classical Immune Cells in Cancer Immunotherapy (C5)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Immunotherapy: Combinations (C5)


Organizer(s) Chris Boshoff, Lieping Chen and Lisa Coussens
March 23—27, 2018
Fairmont The Queen Elizabeth • Montreal, Québec Canada
Discounted Abstract Deadline: Nov 21, 2017
Abstract Deadline: Dec 19, 2017
Scholarship Deadline: Nov 21, 2017
Discounted Registration Deadline: Jan 16, 2018

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by BioLegend, Inc., Bristol-Myers Squibb Company, Cancer Research UK, Cell Research, Genentech, Inc., Incyte Corporation, MedImmune, Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology,Takeda Pharmaceutical Company Limited, TESARO, Inc. and Thermo Fisher Scientific Inc.

Summary of Meeting:
By 2025, most patients with cancer will receive immunotherapy as part of their treatment regimen. This symposium will cover the most critical topics integral to this vision: How can we integrate, sequence or combine immunotherapy with standard-of-care cytotoxic therapy, radiotherapy and targeted therapies? Which preclinical models are best predictive of combination approaches? How do we combine immune agonists as well as molecules inhibiting immune-suppressive pathways with checkpoint inhibitors? What are the rational combinations for cancer vaccines and viro-therapy? Which combinatorial approaches could prevent or treat adaptive mechanisms of resistance? Most immunotherapies are being developed in isolation, or being tested as single agents in preclinical models or in clinical studies. This conference helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical. Overall, the objectives of this meeting are to: 1) Elucidate rational combinations for immunotherapy; 2) Discuss preclinical and other models to inform combinatorial approaches; 3) Understand the relevance for biomarker approaches; and 4) Provide insights into the latest preclinical and clinical data for immunotherapy combinations.

View Meeting Program

Scholarships/Awards

Anonymous Donor Scholarship Recipients

Alvaro de Mingo Pulido
Moffitt Cancer Center, USA

Simone A. Minnie
QIMR Berghofer Medical Research Institute, Australia

Sabrin Mishel
University of Toronto, Canada

Adrienne Rothschilds
Massachusetts Institute of Technology, USA

National Cancer Institute (NCI) Scholarship Recipients

Casey Ager
University of Texas MD Anderson Cancer Center, USA

Jiemiao Hu
University of Texas MD Anderson Cancer Center, USA

Hayley S. Ma
Sidney Kimmel Comprehensive Cancer Center, USA

Bradley N. Mills
University of Rochester, USA

Christopher D. Zahm
University of Wisconsin-Madison, USA